Nicotine pod

Phase 2Small molecule

YYale University

Nicotine pod is one of 107 small molecule programs targeting Parkinson disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

106

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson DiseaseActive, not recruiting

CognitionActive, not recruiting

Smoking CessationActive, not recruiting

Parkinson DiseasePhase 2

Active, not recruiting

CognitionPreclinical

Active, not recruiting

Smoking CessationPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

191 competitors in Cognition

#DrugCompanyPhaseTrials

Provigil

NNuvo Research GmbH

Phase 3

1 2

Activella

Eli Lilly

Preclinical

2 3

Estrace

Novo Nordisk

Preclinical

2 4

Galvus

Novartis

Preclinical

1 5

Depo-Provera

Pfizer

Preclinical

1 6

Resotran

Takeda

Preclinical

1 7

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 8

Marinol

Alnylam Pharmaceuticals

Preclinical

1 9

Veramyst

GSK

Preclinical

1 10

Ozempic

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Smoking Cessation

NCT07487818

Clinical

Trials by Indication[1]

Abuse Potential1 trial

Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol

Completed·YYale University·Phase 1·NCT03580525·24 enrolled

Pilot Study1 trial

Texting to Promote Tobacco Abstinence in Emergency Department Smokers: A Pilot Study

Completed·YYale University·Phase 1·NCT02081144·60 enrolled

Alcohol1 trial

Combination Nicotine Replacement for Alcoholic Smokers

Completed·YYale University·Phase 4·NCT00064844·96 enrolled

Vaccination1 trial

Nicotine Vaccination and Nicotinic Receptor Occupancy

Completed·YYale University·Phase 2·NCT00996034·14 enrolled

Smoking1 trial

Smoking by IV Pulsed Nicotine

Completed·YYale University·Phase 1·NCT04488744·13 enrolled

6 more indications

Liver1 trial

The Effect of Nicotine Delivery Rate on Reinforcement

Completed·YYale University·Phase 1·NCT03134339·18 enrolled

Parkinson disease1 trial

Pilot Trial of Transnasal Nicotine in Parkinson Disease

Completed·EEl Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez·Phase 2·NCT03865121·6 enrolled

MPA1 trial

Impact of Flavors on Nicotine Perception and Self-Administration Via E-cigarettes

Completed·YYale University·Phase 2·NCT04038515·54 enrolled

Interaction1 trial

The Interaction of Flavor With Nicotine Form in Adult Smokers

Completed·YYale University·Phase 1·NCT04262817·20 enrolled

Cognition1 trial

Acute Effects of Vaping Nicotine on Cognition in Young Adults

Completed·YYale University·N/A·NCT04901208·8 enrolled

Smoking Cessation1 trial

Using Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation

Recruiting·MMayo Clinic·Preclinical·NCT07487818·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Nicotine pod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nicotine pod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nicotine pod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yale University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: YYale University

Nicotine pod

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Abuse Potential1 trial

Pilot Study1 trial

Alcohol1 trial

Vaccination1 trial

Smoking1 trial

Liver1 trial

Parkinson disease1 trial

MPA1 trial

Interaction1 trial

Cognition1 trial

Smoking Cessation1 trial

References

Drug Info

Quick Facts

Related News